NCT01484236 National Lymphangioleiomyomatosis Registry, France
| NCT ID | NCT01484236 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vincent COTTIN |
| Condition | Lymphangioleiomyomatosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2012-01 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2012-01 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
RE-LAM-CE is a registry of lymphangioleiomyomatosis cases in France. its aim is to determine the incidence and prevalence of lymphangioleiomyomatosis in France, including demographic information and information concerning the timing and modalities of diagnosis. Based on the registry, we will set up a prospective cohort of patients. The database will include detailed medical information, particularly regarding progression of the respiratory function.
Eligibility Criteria
Inclusion Criteria: * Patients with sporadic lymphangioleiomyomatosis or associated with Tuberous sclerosis. * patients diagnosed or hospitalized or seen in consultation since 01/01/2008 Exclusion Criteria: * None
Contact & Investigator
Vincent Cottin, MD
📞 33-427-857-700
Vincent Cottin, MD
PRINCIPAL INVESTIGATOR
Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires, HCL
Frequently Asked Questions
Who can join the NCT01484236 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphangioleiomyomatosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01484236 currently recruiting?
Yes, NCT01484236 is actively recruiting participants. Visit ClinicalTrials.gov or contact Vincent COTTIN to inquire about joining.
Where is the NCT01484236 trial being conducted?
This trial is being conducted at Lyon, France.
Who is sponsoring the NCT01484236 clinical trial?
NCT01484236 is sponsored by Vincent COTTIN. The principal investigator is Vincent Cottin, MD at Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires, HCL. The trial plans to enroll 200 participants.